RUBY — Rubius Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft
Brief: Rubius Therapeutics Says On Feb 6, Co Was Notified By Nasdaq That Co Will Be Delisted On Feb 15
Rubius Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Rubius Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Rubius Therapeutics Explores Strategic Alternatives & Leadership Changes
Brief: Rubius Therapeutics Enters Into Payoff Letter With SLR Investment
U.S. STOCKS ON THE MOVE-Akouos, Core & Main, Revance Therapeutics
U.S. STOCKS ON THE MOVE-Planet Labs, Catalyst Pharma, Akero
Rubius Therapeutics falls as co terminates trials of some drugs
Brief: Rubius Therapeutics Announces Strategic Update
Brief: Rubius Therapeutics To Provide Strategic Update
Brief: Rubius Therapeutics Posts Q2 Loss Per Share $0.49
Rubius Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Rubius Therapeutics Gets Notice From Nasdaq Notifying Co Did Not Satisfy Certain Continued Listing Requirement
Brief: Rubius Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million – SEC Filing
Brief: Rubius Therapeutics To Present Trials In Progress Poster For The Phase 1/2 Clinical Trial Of Rtx-224 In Select Advanced Solid Tumors At The 2022 American Society Of Clinical Oncology Annual Meeting